Oncogenic KRAS leads to an accumulation of constitutively active (GTP-bound) KRAS proteins leading toward the activation of diversified downstream signaling pathways such as the Ras/RAF/MEK/ERK signaling pathway and the PI3K/AKT signaling pathways, which were extensively studied in the Ras–effector cancer context (Romano et al, 2014). This evidence concerns the gene KRAS and cancer.